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Depression as a Potential Modulator
of Beta-Adrenergic–Associated
Leukocyte Mobilization in Heart Failure Patients
Laura S. Redwine, PHD,*† Petra H. Wirtz, PHD,‡ Suzi Hong, PHD,* Jos Bosch, PHD,§
Michael G. Ziegler, MD,† Barry Greenberg, MD,† Paul J. Mills, PHD*
La Jolla, California; Zurich, Switzerland; and Birmingham, United Kingdom
Objectives The aim of this study was to determine whether depressive symptoms are related to alterations in the sensitivity
of peripheral blood mononuclear cells to -adrenergic agonists in patients with heart failure (HF) by measuring
in vitro chemotaxis (CTX) to isoproterenol at rest and after acute exercise in patients with HF and controls.
Background Clinical outcomes are worse for patients with HF presenting with symptoms of depression. Sympathetically mod-
ulated immune dysregulation associated with depression may be one mechanism leading to worse prognosis.
Methods Seventy-seven patients with HF and 44 controls (mean age 56.4  1.3 years) completed the Beck Depression
Inventory and a 15-min mild-graded exercise task on a stationary bicycle. Exercise intensity was kept relative to
fitness levels for all participants by gradually increasing resistance to reach a Borg scale subjective rating of
12 to 13, “somewhat hard.” Plasma norepinephrine and epinephrine levels were measured before and after ex-
ercise. Chemotaxis to isoproterenol was determined by measuring in vitro peripheral blood mononuclear cell
migration through a modified Boyden chamber.
Results In patients with HF, depressive symptom severity was associated with greater CTX after exercise (p  0.001).
Higher resting norepinephrine in patients with HF was also associated with increased CTX to exercise
(p  0.03).
Conclusions Patients with HF with higher depressive symptoms and norepinephrine exhibited increased peripheral blood
mononuclear cell CTX to isoproterenol to mild exercise, suggesting greater -adrenergic sensitivity. Increased
immune migration in patients with HF who have elevated depressive symptoms could be associated with cardiac
remodeling and HF disease progression. (J Am Coll Cardiol 2010;56:1720–7) © 2010 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.064s
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ihe prevalence of depression ranges from 20% to 45% in
atients with symptomatic heart failure (HF) and corre-
ponds with significantly greater morbidity and mortality
1). However, the biobehavioral pathways linking depres-
ion with adverse outcomes in HF are unclear. One poten-
ial mechanism is depression-associated dysregulation of
euroendocrine modulation of immune responses to stress
nd exercise (2), which may be injurious to the cardiovas-
ular system (3), leading to worse prognosis in HF (4,5).
rom the *Department of Psychiatry, University of California, San Diego, La Jolla,
alifornia; †Department of Medicine, University of California, San Diego, La Jolla,
alifornia; ‡Department of Clinical Psychology and Psychotherapy, Psychological
nstitute, University of Zurich, Zurich, Switzerland; and the §School of Sport and
xercise Sciences, University of Birmingham, Birmingham, United Kingdom. This
ork was supported by grants HL-073355 and HL-57265 from the National Heart,
ung, and Blood Institute. All authors have reported that they have no relationships
o disclose. Stephen Gottlieb, MD, served as Guest Editor for this paper.n
Manuscript received July 30, 2009; revised manuscript received April 22, 2010,
ccepted April 26, 2010.Autonomic innervation and regulation of the immune
ystem are well recognized (6,7). Sympathetic activation
uring stress and exercise elicits the release of leukocytes
rom the spleen, lymph nodes, and blood vessel subendo-
helia into the bloodstream (8,9). These immune cells
xpress greater surface -adrenergic receptor density and
ensitivity (9–11). The endogenous -adrenergic neurohor-
ones norepinephrine (NE) and epinephrine (EPI) can
hereby regulate immune mobility, as powerful chemoat-
ractants (6,12). Additional inflammatory markers also re-
pond to exercise-related increases in catecholamines in
atients with coronary artery disease patients compared with
ontrols (13).
Depression is associated with modified sympathetic and
eurohormonal activation to stress and exercise, including
ncreased NE and EPI (14). Thus, depression may alter
mmune responses to stress and exercise through changes in
euroendocrine-immune interactions. Indeed, depression is
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November 16, 2010:1720–7 Immune Migration, Depression, and HFssociated with increased leukocyte sensitivity to stress hor-
ones (15) and greater pro-inflammatory responses to stress
nd physical exertion (2,3). Our research suggests that patients
ith HF with elevated depressive symptoms also exhibit
ugmented immune migration processes to exercise (16,17).
lthough the clinical relevance of these findings remains to
e elucidated, excessive leukocyte mobilization can elicit
eukocyte infiltration into myocardial interstitium, which
an underlie injury to the cardiovascular system (4,5).
In light of prior research, the primary objective of the
resent study was to investigate the relationship between
epressive symptoms in patients with HF and leukocyte
obility toward a -adrenergic agonist in response to
hysical exertion, as a model to explore changes in immune
ell sensitivity to neuroendocrine modulation in this group.
his was done by assessing depression symptoms and in
itro chemotaxis (CTX) of peripheral blood mononuclear
ells (PBMC) to isoproterenol (CTX-I) at rest and after
cute exercise, comparing patients with HF and non-HF
ontrols. Furthermore, the influence of endogenous sympa-
hetic activity on these relationships was explored. The
etermination of a link between depression and neuroim-
une dysregulation in patients with HF may suggest one
echanism that leads to worse HF outcomes.
ethods
tudy participants. Included in the study were 124 sub-
ects (80 patients with HF and 44 non-HF controls)
ssessed for in vitro CTX-I, depressive symptoms, physical
unction, and demographic variables from 2005 to 2009.
atients were recruited from the San Diego Veterans Affairs
edical Center and the University of California-San Di-
go, Medical Center as part of a larger study on the effects
f depression on neuroimmunity in HF. Control subjects
ere recruited through advertisements and word-of-mouth
eferrals.
Inclusion criteria for all subjects were age 30 to 85 years,
lood pressure 180/110 mm Hg, and men and women of
ll ethnicities and races. Patients with HF were in New
ork Heart Association functional classes II through IV;
ad symptoms of HF for at least 3 months optimally treated
ith -blockers, diuretics, and angiotensin-converting en-
yme inhibitors; and had systolic dysfunction, defined by an
jection fraction 45%, or diastolic dysfunction with pre-
erved ejection fraction. Left ventricular ejection fraction
as assessed by echocardiography. A 6-min walk test
ssessed physical function capacity (18). Exclusion criteria
ncluded recent myocardial infarction (1 month), recent
troke or significant cerebral neurological impairment, se-
ere chronic obstructive pulmonary disease, major depres-
ion, and other psychiatric illnesses.
The protocol was approved by the University of
alifornia-San Diego, Institutional Review Board, and
articipants gave written informed consent. The study was werformed in accordance with
he principles of the Declaration
f Helsinki.
epressive symptom severity.
epressive symptoms were as-
essed with the 21-item Beck
epression Inventory (BDI), on
hich scores 10 indicate possi-
le clinical depression (19). The
DI was developed to assess
epressive symptoms that cor-
espond to the Diagnostic and
tatistical Manual of Mental
isorders-Fourth Edition, cri-
eria for major depressive disorder (20). A modified
tructured Clinical Interview for DSM-IV (21) was used
o evaluate for major depressive disorder. Those diag-
osed with major depressive disorder were referred to
heir treating physicians but allowed to remain in the
tudy.
xercise testing. Testing began at approximately 11 AM.
articipants abstained from physical exercise, alcohol, aspi-
in, and caffeinated beverages the evening before testing and
rom food and drink (other than water) for 2 h before
esting. An intravenous catheter was placed in the antecu-
ital vein at least 1 h before testing, and blood samples were
btained before and immediately after exercise, all while the
ubject was in an upright, sitting posture. A blood pressure
uff was placed on the opposite arm of the intravenous
atheter and was connected to a Dinamap machine (GE
ealthcare, Milwaukee, Wisconsin) for automatic measure-
ents of heart rate and systolic and diastolic blood pressure
hroughout the session. Subjects performed a mild graded
tationary bicycle task (Viasprint 150p, Viasys, Yorba Linda,
alifornia) consisting of a 5-min warm-up, 10 min at steady
tate, and a 2-min cool-down. The Borg Rating of Per-
eived Exertion Scale (22) was used to obtain similar
xercise intensity relative to existing fitness levels of all
articipants; the resistance (watts) was gradually in-
reased during the warm-up period to reach a rating of 12
o 13 (“somewhat hard”) which was maintained for the
0-min steady-state period by adjusting the resistance
nd speed of cycling. On the basis of our previous studies
23), a rate of perceived effort of 12 to 13 consistently
orresponds to 65% to 70% of peak oxygen uptake
egardless of fitness levels.
TX of PBMC assay. Isoproterenol (1, 10, and 100
mol/l) was used as a chemoattractant, as in previously
eported methods (24). Briefly, at pre- and post-exercise
ime points, 10 ml of blood was collected into heparinized
ubes and processed within 3 h. PBMCs were separated
rom whole blood with Ficoll-Hypaque and resuspended in
erum-free media. Cells were incubated in the dark for 45
in at room temperature, shaking lightly with 0.1 mol/l
alcein acetoxymethyl ester at 2  106 cells/ml (25). Cells
Abbreviations
and Acronyms
BDI  Beck Depression
Inventory
CTX  chemotaxis
CTX-I  chemotaxis to
isoproterenol
EPI  epinephrine
HF  heart failure
NE  norepinephrine
PBMC  peripheral blood
mononuclear cellere washed and resuspended to 3  106 cells/ml in media
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Immune Migration, Depression, and HF November 16, 2010:1720–7ith 0.1% bovine serum albumin (CTX buffer). In a
odified Boyden chamber (Neuro Probe, Inc., Gaithers-
urg, MD), 29.5 l of isoproterenol or CTX buffer was
ipetted to the bottom wells. Twenty microliters of cell
uspension was pipetted on a membrane above the chemoat-
ractants and incubated for 2 h at 37°C. The membrane was
hen submerged in phosphate-buffered saline, and non-
igrated cells were scraped away with cotton swabs
ampened with phosphate-buffered saline. Once dry, the
embrane was read by a fluorescence plate reader (Cyto-
luor, MTX Lab Systems, Inc., Vienna, Virginia) at an
xcitation of 485 nm and emission of 530 nm.
E and EPI measures. A subgroup of 80 patients with HF
nd control subjects also had blood drawn into Vacutainer
ubes (BD Biosciences, San Jose, California) coated with
thylenediaminetetraacetic acid for catecholamines, NE, and
PI. Samples were centrifuged, and plasma was stored at
80°C until analysis. Plasma NE and EPI levels were deter-
ined using a catecholamine-methyl-transferase–based ra-
ioenzymatic assays with a pre-concentration step that ex-
racted catecholamines from 1 ml plasma and concentrated
hem in 0.1 ml of dilute acid, following previous methods (26).
he interassay coefficient of variation was 11%, and the
ntra-assay coefficient of variance was 6.5%.
tatistical analyses. Calculations were performed using
PSS version 15 (SPSS, Inc., Chicago, Illinois). Cases with
issing data were excluded using listwise deletion (27).
kewed data distribution was determined by the Kolmogorov-
mirnov test, and variables not normally distributed were log
ransformed. We controlled for the cardiovascular risk factors:
Sociodemographic and Medical CharacteristicsTable 1 Sociodemographic and Medical Cha
Variable Patient
BDI score 11.5
Age (yrs) 59.5
Men 8
Body mass index (kg/m2)† 31.7 0.8
Mean arterial blood pressure (mm Hg)* 92.6 2.2
Current smokers 1
HF severity
6-min walking distance (m) 339.2 1
Ejection fraction (%) 32.0
NYHA functional class II 8
NYHA functional class III 1
Medications
ACE inhibitors
Beta-blockers 9
CCBs 1
Statins 6
Aspirin 6
Diuretics
Antiarrhythmic agents 1
Digoxin 5
Data are expressed as mean  SEM (range) or as percentages. *Mea
systolic blood pressure 2/3 diastolic blood pressure). †Body mass inACE  angiotensin-converting enzyme; BDI  Beck Depression Inventory; C
Heart Association.ge, sex, body mass index, and physical function (distance
alked in 6 min) in all analyses.
Group differences in sociodemographic and medical
haracteristics (Table 1) were computed using independent
tests or, for categorical data, Kruskal-Wallis tests.
epeated-measures analyses of covariance were performed
n CTX data with 2 between factors for group (patients
ith HF and non-HF controls), 3 within factors for dose of
soproterenol (1, 10, and 100 nmol/l), and 2 within factors
or time (before and after exercise). The Greenhouse-
eisser correction was applied to correct for multiple
omparisons. Post hoc analyses determined baseline and
xercise response differences between patients with HF and
on-HF controls.
Linear regression analyses determined associations be-
ween circulating catecholamine levels, heart rate, and
TX-I 10 nmol/l (this concentration was chosen because it
licited a middle range of immune responsiveness), control-
ing for age, sex, body mass index, and physical function.
e tested depressive symptom severity modulation accord-
ng to Baron and Kenny (28): to test for mediation, we
ntered BDI score as a covariate. To test for moderation, we
ntered the interaction between BDI score and group (HF
tatus) while controlling for group and BDI score. Similarly,
e entered the interaction between BDI score, group, and
E level (or heart rate) while controlling for BDI score,
roup, and NE (or heart rate). To graphically illustrate our
ndings, we split BDI scores into 10 and 10 and both
eart rate and NE into “high” and “low” using median split.
e Study Subjectsristics of the Study Subjects
HF Controls p Value
–34) 5.4 0.88 (0–44) 0.002
–83) 52.2 1.3 (34–84) 0.001
47.6% 0.001
4–59.0) 28.3 .79 (18.5–54.5) 0.033
–141.9) 98.7 1.5 (77.4–123.7) 0.038
10.6% 0.32
0–624) 493 13.7 (198–975) 0.001
–70) Not measured
0% 0.001
0% 0.001
0% 0.001
0% 0.001
0% 0.001
0% 0.001
5.7% 0.001
0% 0.001
0% 0.001
0% 0.001
ial pressure was calculated from resting blood pressure readings (1/3
calculated as weight in kilograms divided by height in square meters.of thracte
s With
0.85 (0
1.3 (30
0.8%
5 (19.
(59.0
6.1%
0.2 (10
1.1 (10
5.5%
2.7%
73%
6.2%
2.1%
4.3%
3.3%
88%
3.8%
2.5%
n arter
dex wasCB  calcium-channel blocker; HF  heart failure; NYHA  New York
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ociodemographic and medical characteristics of the
tudy groups. Of the 124 subjects who participated in the
tudy, 6 were dropped from analyses because of missing
ata, including BDI scores (2 subjects with HF) and/or
-min walk tests (3 non–HF controls and 1 subject with
F). According to Kolmogorov-Smirnov tests, BDI scores
nd NE were not normally distributed (p  0.002 and p 
.005, respectively). Standard transformation (e.g., square
oot and log) did not normalize the distribution of BDI
cores (p  0.011), while log transformation yielded a
ormal distribution for NE (p  0.51). However, a normal
robability P-P plot suggested that log-transformed BDI
cores had a linear pattern with only minor deviations from
he line fit to the points on the probability plot, indicating
hat BDI scores approached a normal distribution. Table 1
resents the biological and medical characteristics of pa-
ients with HF and controls. None of the control subjects
nd 93% of the patients with HF were taking -blockers,
ncluding 67% taking carvedilol, which has 1-blocking,
2-blocking, and weak 1-blocking activity, and 21% taking
1-specific agents such as metoprolol. No differences were
ound between patients with HF taking -blockers or not
aking -blockers for CTX-I at rest (p  0.21) or response
o exercise (p  0.50). Although patients with HF had
igher BDI scores (p  0.001), 3 of the non-HF subjects
nd only 1 of the patients with HF were diagnosed with
ajor depressive disorder. BDI scores were 7.5  4.5 for
atients with HF taking 1-specific blockers, 12.8  8.5
or those taking 1- and 2-specific blockers, and
3.4  7.1 for those not taking -blockers. Beta-blocker
ypes or not taking -blockers did not differ for BDI scores
fter controlling for New York Heart Association functional
Figure 1 In Vitro Chemotaxis to
-Agonist Before and After Exercise
Stimulation index (chemotaxis to isoproterenol/random migration) in a dose
response to isoproterenol in patients with heart failure (HF) and controls at
rest and in response to exercise. Data are expressed as mean  SEM.llass (p  0.25). The lack of an association between
-blocker use and depressive symptoms is consistent with
he larger literature in non-HF populations (29).
TX-I at baseline and after exercise. Repeated-measures
nalysis of covariance indicated that patients with HF and
on-HF controls differentially responded to varying doses
f isoproterenol (1, 10, and 100 nmol/l) while controlling
or age, sex, body mass index, and physical function (HF
tatus-by-dose interaction: F[6, 112]  4.2, p  0.018)
fter Greenhouse-Geisser correction (Fig. 1). To determine
he characteristics of the differences, post-hoc analyses
evealed that at rest, patients with HF showed positive
TX-I dose responses (1, 10, and 100 nmol/l), while
on-HF controls did not exhibit CTX-I dose responses
HF status-by-dose interaction at rest: p  0.002). How-
ver, in response to exercise, both groups had similar
ositive CTX-I dose responses and did not differ from each
ther (HF status effect: p  0.47).
epressive symptoms and CTX-I before and after exercise.
egression analyses revealed that in both groups, higher
DI scores were associated with a trend for lower CTX-I at
aseline (p  0.099). In response to exercise, BDI scores
ppeared to moderate an increased CTX-I response in
atients with HF compared with non-HF controls (t 3.3,
 0.001, R2  0.11) (Table 2).
E, EPI, heart rate, and CTX-I response to exercise:
nteraction with depression. A linear regression analyses
ound that higher resting NE levels were associated with
reater CTX-I responses to exercise in patients with HF but
ot in non-HF controls (NE-by-HF interaction: p  0.03,
R2  0.045) (Table 2). This suggests that basal sympa-
hetic activation may moderate CTX-I in response to
xercise in patients with HF. Meanwhile, baseline EPI
egression Outcomes Predicting Changes inTX-I to 10 nmol/l Response to Exercis WithDI and NE as P tential Moderators
Table 2
Regression Out omes Predicting Changes in
CTX-I to 10 nmol/l Response to Exercise With
BDI and NE as Potential Moderators
Coefficients
Model R2 t p Value 
Risk factors 0.024
Age 0.487 0.628 0.001
Sex 0.181 0.857 0.011
BMI 1.361 0.178 0.005
6-min walking
distance
0.302 0.764 0.0001
HF status 3.014 0.004 0.985
Predictors 0.146
NE 3.125 0.003 0.171
BDI score 3.119 0.003 0.091
Interactions 0.153
HF status  NE 2.205 0.031 0.118
HF status  BDI score 3.446 0.001 0.105
he final regression model and coefficients are shown. The regression models were as follows:
ardiovascular risk factors (step 1: age, sex, BMI, 6-min walking distance, HF status), predictors
f CTX-I (step 2: resting NE and BDI), and interaction variables (step 3: HF status  NE and HF
tatus  BDI score).
BMI  body mass index; other abbreviations as in Tables 1 and 2.evels and HR were not associated with CTX-I in either
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Immune Migration, Depression, and HF November 16, 2010:1720–7roup (p  0.50 and p  0.95, respectively). Furthermore,
here were no interactions between BDI and NE, EPI, or
eart rate for CTX-I in either group.
E, EPI, and heart rate reactivity to exercise: interaction
ith depression. Neither NE nor EPI significantly in-
reased from before to after exercise in either group (p 
.95 and p  0.29, respectively), and patients with HF and
on-HF controls did not differ in NE or EPI levels in
esponse to exercise (p  0.32 and p  0.12, respectively).
DI scores were also not significantly associated with NE or
PI levels at baseline or in response to exercise.
Heart rate did not differ between patients with HF and
on-HF controls at baseline (p  0.22) or in response to
xercise (p  0.32). However, exercise produced significant
ncreases in heart rate in both groups (p  0.003, R2 
.29). Furthermore, greater depressive symptom levels were
elated to higher baseline heart rate, even after controlling
or HF status (p  0.016, R2  0.045).
iscussion
he present results suggest that immune cell mobility is
ikely differentially regulated by neuroendocrine processes in
atients with HF compared with non-HF controls. More-
ver, elevated depressive symptoms in patients with HF may
urther augment immune cell motility to neurohormones in
eaction to physical exertion. Both at rest and in response to
xercise, PBMCs from patients with HF exhibited a CTX-I
ose response in vitro. This suggests that patients with HF
re sensitive to changes in adrenergic stimuli during both
nactivity and activity. Meanwhile, non-HF controls had
ittle response to isoproterenol at rest, whereas in response
o exercise, they exhibited an increase in CTX at higher
oncentrations of isoproterenol. These findings are consis-
ent with observations that physically healthy adults have
reater -adrenergic receptor density and sensitivity re-
ponses to acute challenges (11), which may underlie in-
reased homing of lymphocytes to higher concentrations of
-agonists (6,30).
Acute challenges such as exercise tasks create a window
nto complicated physiological processes (31) and can reveal
euroimmune dysregulation in patients with cardiovascular
isease that may be masked under resting conditions (13).
ur principal finding was that in response to exercise,
atients with HF with higher depression scores had greater
BMC mobility to a -adrenergic agonist (isoproterenol)
ompared with non-HF controls (Fig. 2). Meanwhile,
atients with HF with lower depression symptoms re-
ponded minimally to exercise, which is to be expected in a
roup taking -blockers. Thus, patients with HF with high
epressive symptoms appeared to override the effects
f -blockers. Our results are consistent with findings that
sychological factors are associated with reduced -blockade
fficacy in response to exercise challenge (32).
NE, EPI, and heart rate were assessed to explore endog-
nous sympathetic and neuroendocrine influences on TX-I (Table 3). Unexpectedly, NE and EPI levels did not
ncrease during exercise in either patients with HF or
on-HF controls. This is likely due to less exertion expen-
iture from the exercise task in the present study (approx-
mately 65% to 70% of peak oxygen uptake) because of the
imited exercise capacity of patients with HF. In contrast,
arious investigations of non-HF cardiovascular disease
atients have used the standard Bruce protocol to obtain
eak oxygen uptake to examine catecholamine responses
33). Also unexpectedly, there were no differences observed
etween patients with HF and non-HF controls for NE or
PI levels or differences between groups in exercise-induced
ncreases in NE and EPI levels. Furthermore, heart rate was
ower in patients with HF than in non-HF controls. These
esults appear in contrast to what is known about HF, being
n a state of generalized sympathetic activation (34). How-
ver, medications regularly prescribed to treat HF, such as
-blockers, likely reduced sympathetic activity in the pa-
ients with HF.
Meanwhile, patients with HF with elevated resting NE
evels had an increase in CTX-I in response to exercise,
hereas, exercise-induced changes in NE, EPI, and heart
ate were not associated with CTX-I (Table 3). These
ndings are consistent with literature over 2 decades sug-
esting that acute adrenergic exposure during exercise is not
ong enough to generate structural changes in lymphocyte
drenergic receptors (10). Instead, the immune cells that
eside in lymphatic tissue, and that are released with
hysical exertion, are likely to already have altered sensitivity
o -agonists. This suggests systemic neuroimmune dys-
egulation, which may have clinical relevance in that altered
Figure 2 Chemotaxis Responses to Exercise in
Subjects With High and Low Depressive Symptoms
Change scores (post-exercise minus pre-exercise) and chemotaxis to 3 concen-
trations of isoproterenol (1, 10, and 100 nmol/l) in patients with heart failure
(HF) and non-HF controls. High (hi) versus low (lo) depression was determined
by scores of 10 and 10 on the Beck Depression Inventory (BDI). Data are
expressed as mean  SEM.-adrenergic receptor expression dynamics predicts the
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November 16, 2010:1720–7 Immune Migration, Depression, and HFevelopment of preclinical states such as greater left ven-
ricular mass and blood pressure (35,36).
Although we found that both depressive symptoms and
esting NE levels were positively associated with CTX-I
o exercise in patients with HF (Figs. 3 and 4), they were
ndependent of each other. Therefore, the effects of
levated depression symptoms on CTX to -agonists
ere likely not directly related to heightened basal NE
evels in patients with HF. Instead it may again suggest
euroimmune dysregulation, because chronic psycholog-
cal distress is known to be associated with down-
orrelation Coefficients Among VariablesTable 3 Correlation Coefficients Among Variables
Variable Group Resting HR
Peak HR
During Exercise
Averag
During
BDI score Non-HF 0.394* 0.053 0.
HF 0.139 0.098 0.
Resting HR Non-HF 1.00 0.334* 0.
HF 0.460* 0.
Peak HR during
exercise
Non-HF 1.00 0.
HF 0.
Average watts
during exercise
Non-HF 1.
HF
Baseline NE Non-HF
HF
Baseline EPI Non-HF
HF
Pre- to post-
exercise NE
Non-HF
HF
Pre- to post-
exercise EPI
Non-HF
HF
p  0.01 and †p  0.05.
CTX-I  chemotaxis to isoproterenol; EPI  epinephrine; HR  heart rate; NE  norepinephrine
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Figure 3 Chemotaxis Responses to Exercise
With Differential Depression and NE Levels
Change scores (post-exercise minus pre-exercise) and chemotaxis to 3 concen-
trations of isoproterenol (ISO) (1, 10, and 100 nmol/l). Data from patients with
HF and non-HF controls were combined. High versus low depression was deter-
mined by scores of 10 and 10 on the BDI. High versus low norepinephrine
(NE) levels were determined by a median split. Data are expressed as mean 
SEM. Abbreviations as in Figure 2.egulated -adrenergic receptor expression (37). This in
urn would likely reduce chemoattraction sensitivity to
-agonists, as seen in chronically stressed Alzheimer
aregivers (25). However, patients with HF with elevated
epressive symptoms appear to not follow this expected
attern. Thus, the mechanism that induces increased
BMC mobilization to -agonists in patients with HF
ith depression has yet to be determined.
tudy limitations. Limitations of this study include a
isproportionate number of women in the control group
ompared with patients with HF. However, sex was
ts
se
Baseline Pre- to Post-Exercise
NE EPI NE EPI CTX-I (10 nmol/l)
0.076 0.064 0.081 0.139 0.179
0.006 0.007 0.080 0.087 0.238†
0.243 0.135 0.055 0.129 0.093
0.050 0.184 0.229 0.190 0.146
0.310* 0.350† 0.258 0.141 0.135
0.046 0.050 0.417* 0.208 0.045
0.160 0.074 0.250 0.098 0.010
0.168 0.105 0.029 0.001 0.061
1.00 0.258† 0.442* 0.265 0.093
0.286† 0.293† 0.222 0.320†
1.00 0.041 0.357† 0.125
0.151 0.241 0.151
1.00 0.457* 0.259
0.572* 0.028
1.00 0.178
0.047
abbreviations as in Table 1.
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Figure 4 Chemotaxis Responses to Exercise
in Patients With HF and Controls
Change scores (post-exercise minus pre-exercise) and chemotaxis to ISO (10
nmol/l). Data from patients with HF and non-HF controls are presented. High
versus low depression was determined by median split on the BDI (7 and 7
to depict at least 9 subjects per group). High versus low NE levels were deter-
mined by median split. Data are expressed as mean  SEM. Abbreviations as
in Figures 2 and 3.e Wat
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ere not different when women were removed from the
nalyses (data not shown). Nonetheless, future studies
ith larger cohorts of women should be performed to
xplore whether there are sex differences in neuroimmune
odulation in patients with HF with depression. A
otential limitation was the heterogeneous population,
ncluding patients with HF with preserved systolic func-
ion (n  11) and those with systolic dysfunction (n 
9). However, these groups did not differ in BDI scores
p  0.20), CTX-I at baseline (p  0.36), or response to
xercise (p  0.79). It is important to note that the
ssociations found in this study are correlational and
herefore may not be causative and are based on relatively
ew patients. Further study is needed to replicate our
ndings and research is needed to tease apart the inter-
ctions between depression, sympathetic activity, and HF
tatus. In addition, research is necessary to determine if
ardiac structural changes are linked with the -adrenergic-
ssociated immune activation in this group to reveal clinical
mplications of these results.
onclusions
ur results suggest that patients with HF with greater
epressive symptoms are associated with an augmented
TX-I response to physical exertion. This may indicate an
ncrease in -adrenergic sensitivity in patients with HF with
epressive symptoms that override medications prescribed
o reduce sympathetic activity. Furthermore, chronic sym-
athetic activation and depressive symptoms that occur
oncomitantly in patients with HF could lead to even
reater immune mobility in this group, which may promote
ncreased nonspecific infiltration of immune cells into car-
iovascular tissue and result in remodeling. Further under-
tanding of the relationship between depressive symptoms
nd immune responses to adrenergic agonists may be useful
or the development of potential treatments to abrogate
ncreased morbidity and mortality in patients with HF with
epression.
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